Lung Neoplasm

In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictiv… (full text at CIViC)

PMID 26137564 · Mendell et al., 2015 · Open in CIViC

A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.

PMID 30624546 · Hong et al., 2019 · Open in CIViC

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer had initially responded with a partial response to the NTRK inhibitor entrectinib for 12 months. Upon pro… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer progressed after 12 months treatment with the NTRK inhibitor entrectinib with the emergence of an NTRK3 G… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

25 tumors from individuals with lung adca who have <= 10 pack-year smoking history underwent whole exome sequencing and RNA-seq. 5 tumors did not identify an established oncogenic driver. In one (tumo… (full text at CIViC)

PMID 35247929 · Hunihan et al., 2022 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PAPPA2 Y1520* nonsense mutation, treated with pembrolizumab monotherapy, was associated with a 4 … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.

PMID 26745678 · Li et al., 2016 · Open in CIViC

PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.

PMID 25928036 · Xu et al., 2015 · Open in CIViC

Cell line NCI-H1703 is PDGFRA amplified and KIT wild-type. NCI-H1703 was treated with a PDGFRA inhibitor, imatinib or sunitinib. The IC50 of imatinib or sunitinib was lower in PDGFRA amplified NCI-H… (full text at CIViC)

PMID 19755855 · Ramos et al., 2009 · Open in CIViC

In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression … (full text at CIViC)

PMID 19366796 · McDermott et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

HCC827 cell lines harboring activated PI3K (HCC827 p110α E545K cells) were more resistant to gefitinib in vitro (IC50, 1 μM) compared with those harboring GFP alone (IC50, 0.01 μM). The presence of p1… (full text at CIViC)

PMID 16906227 · Engelman et al., 2006 · Open in CIViC

48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed… (full text at CIViC)

PMID 27304188 · Belchis et al., 2016 · Open in CIViC

Lung adenocarcinoma cell lines with MET exon 14 skipping mutation and PIK3CA mutation (H596) were tested with GDC0941 (pictilisib) alone and with crizotinib. Analysis shows a statistically significant… (full text at CIViC)

PMID 26215952 · Liu et al., 2016 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha … (full text at CIViC)

PMID 19029981 · Engelman et al., 2008 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patien… (full text at CIViC)

PMID 21258250 · Ludovini et al., 2011 · Open in CIViC

In a phase II trial,patients with squamous NSCLC harboring PIK3CA mutations were treated with PI3K inhibitor taselisib. The study was closed for futility at interim analysis with one responder (Respon… (full text at CIViC)

PMID 31158500 · Langer et al., 2019 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with ad… (full text at CIViC)

PMID 26918046 · Jiang et al., 2016 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mut… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous muta… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLE4 deleterious A59E mutation (as determined by Polyphen or SIFT), treated with pembrolizumab m… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective analysis of the Hellmann cohort of 75 patients with non-small cell lung cancer treated with combined PD-1 and CTLA-4 blockade, 6 patients with nonsynonymous PRKDC mutations had a hi… (full text at CIViC)

PMID 32502294 · Chen et al., 2020 · Open in CIViC

PTPRF expression was found to be prognostic for shorter overall survival but was also significantly predictive of improved survival with erlotinib versus placebo in SATURN even in the EGFR wild-type … (full text at CIViC)

PMID 26291013 · Soulières et al., 2015 · Open in CIViC

PTPRF expression was found to be prognostic for shorter overall survival but was also significantly predictive of improved survival with erlotinib versus placebo in SATURN even in the EGFR wild-type s… (full text at CIViC)

PMID 26291013 · Soulières et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PXDNL deleterious P1460T mutation, treated with pembrolizumab monotherapy, was associated with a … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations… (full text at CIViC)

PMID 29127119 · Hayashi et al., 2018 · Open in CIViC

Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from othe… (full text at CIViC)

PMID 22619677 · Zhao et al., 2012 · Open in CIViC

Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds rat… (full text at CIViC)

PMID 26802149 · Dowlati et al., 2016 · Open in CIViC

A phase II clinical study was conducted with 29 patients with Non-Small-Cell Lung Cancer harboring CDKN2A alterations and wild-type Rb. The study reported one patient with a partial response, and six … (full text at CIViC)

PMID 35050752 · Ahn et al., 2020 · Open in CIViC

ASCL1 and RET mRNA levels were examined by microarray analysis in lung cancer samples. High expression of RET (RET-high) correlated with shorter overall survival compared to the RET-low group in patie… (full text at CIViC)

PMID 24037524 · Kosari et al., 2014 · Open in CIViC

Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alterat… (full text at CIViC)

PMID 26370156 · Cheng et al., 2015 · Open in CIViC

In a phase 2 basket trial, patients with small-cell lung carcinoma (SLC) who failed platinum-based chemotherapy and harbored RICTOR amplification were treated with mTOR 1/2 inhibitor vistusertib (AZD2… (full text at CIViC)

Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 A77P was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 A… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 A77S was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 A… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC